Cargando…

Market-driven, value-based, advance commitment (MVAC): accelerating the development of a pathbreaking universal drug regimen to end TB

Detalles Bibliográficos
Autores principales:	Chalkidou, Kalipso, Towse, Adrian, Silverman, Rachel, Garau, Martina, Ramakrishnan, Ganesh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204919/ https://www.ncbi.nlm.nih.gov/pubmed/32332035 http://dx.doi.org/10.1136/bmjgh-2019-002061

Ejemplares similares

How Should the World Pay for a Coronavirus Disease (COVID-19) Vaccine?
por: Towse, Adrian, et al.
Publicado: (2021)

Insights from advancements and pathbreaking research on the minimally invasive treatment of atrial fibrillation
por: Witkowska, Anna, et al.
Publicado: (2021)

ANCIPS 2022 Vizag – Symposium Abstract Telepsychiatry: A pathbreaking way forward
Publicado: (2022)

Mapping Priority Setting in Health in 17 Countries Across Asia, Latin America, and sub-Saharan Africa
por: Li, Ryan, et al.
Publicado: (2016)

Gemcitabine–cisplatin versus MVAC chemotherapy for urothelial carcinoma: a nationwide cohort study
por: Lee, Yong Seong, et al.
Publicado: (2023)

Neoadjuvant chemotherapy with dose dense MVAC is associated with improved survival after radical cystectomy compared to other cytotoxic regimens: A tertiary center experience
por: Lemiński, Artur, et al.
Publicado: (2021)

Value-based tiered pricing for universal health coverage: an idea worth revisiting
por: Chalkidou, Kalipso, et al.
Publicado: (2020)

World leaders commit to bold targets and urgent action to end TB
Publicado: (2018)

Applications of Adductomics in Chemically Induced Adverse Outcomes and Major Emphasis on DNA Adductomics: A Pathbreaking Tool in Biomedical Research
por: Behl, Tapan, et al.
Publicado: (2021)

Ignacio Rodríguez-Iturbe (1942–2022): A review of a pathbreaking academic career combining chance and self-organization
por: Levin, Simon A., et al.
Publicado: (2022)

The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens
por: Khan, Uzma, et al.
Publicado: (2019)

Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort( )
por: Hewison, Catherine, et al.
Publicado: (2022)

Modified MVAC as a Second-Line Treatment for Patients with Metastatic Urothelial Carcinoma after Failure of Gemcitabine and Cisplatin Treatment
por: Lee, Jung Hyun, et al.
Publicado: (2014)

Sharing the British National Health Service around the world: a self-interested perspective
por: Chalkidou, Kalipso, et al.
Publicado: (2013)

Predicting the response of patients with advanced urothelial cancer to methotrexate, vinblastine, Adriamycin, and cisplatin (MVAC) after the failure of gemcitabine and platinum (GP)
por: Kim, Ki Hong, et al.
Publicado: (2015)

Correction to: Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort
Publicado: (2023)

Economic Evaluation for Health Investments En Route to Universal Health Coverage: Cost-Benefit Analysis or Cost-Effectiveness Analysis?
por: Culyer, Anthony J., et al.
Publicado: (2019)

Should Countries Set an Explicit Health Benefits Package? The Case of the English National Health Service()
por: Smith, Peter C, et al.
Publicado: (2017)

Organising Research and Development for evidence-informed health care: some universal characteristics and a case study from the UK
por: Culyer, Anthony J., et al.
Publicado: (2021)

Is intermittent short-course anti-TB regimen as efficient and safe as daily anti-TB regimen for treating childhood TB?
por: Bhaumik, Soumyadeep
Publicado: (2015)

Ending the TB pandemic: the urgency of a new and improved TB vaccine and the World Health Organization's TB Vaccine Accelerator Council
por: Adepoju, Victor Abiola, et al.
Publicado: (2023)

Can Pan-TB shorter regimens be a promising hope for ending TB in India by 2025 in ongoing COVID-19 era?
por: Prasad, Rajendra, et al.
Publicado: (2022)

Accelerating development of new shorter TB treatment regimens in anticipation of a resurgence of multi-drug resistant TB due to the COVID-19 pandemic
por: Tiberi, Simon, et al.
Publicado: (2021)

Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy
por: Sampson, Chris, et al.
Publicado: (2022)

Rival perspectives in health technology assessment and other economic evaluations for investing in global and national health. Who decides? Who pays?
por: Culyer, Anthony, et al.
Publicado: (2018)

Health Technology Assessment capacity development in low- and middle-income countries: Experiences from the international units of HITAP and NICE
por: Tantivess, Sripen, et al.
Publicado: (2017)

Incorporating MCDA into HTA: challenges and potential solutions, with a focus on lower income settings
por: Marsh, Kevin, et al.
Publicado: (2018)

The Cost-Effectiveness of the BEAT-TB Regimen for Pre-Extensively Drug-Resistant TB
por: Muniyandi, Malaisamy, et al.
Publicado: (2023)

Commit* to change? A call to end the publication of the phrase ‘commit* suicide’
por: Nielsen, Emma, et al.
Publicado: (2016)

We need a NICE for global development spending
por: Chalkidou, Kalipso, et al.
Publicado: (2017)

Health technology assessment capacity at national level in sub-Saharan Africa: an initial survey of stakeholders
por: Hollingworth, Samantha A., et al.
Publicado: (2021)

Capacity for health economics research and practice in Jordan, Lebanon, the occupied Palestinian territories and Turkey: needs assessment and options for development
por: Gheorghe, Adrian, et al.
Publicado: (2020)

Medical training for universal health coverage: a review of Cuba–South Africa collaboration
por: Squires, Neil, et al.
Publicado: (2020)

Charging for the use of survey instruments on population health: the case of quality-adjusted life years
por: Teerawattananon, Yot, et al.
Publicado: (2020)

The journey to UHC: how well are vertical programmes integrated in the health benefits package? A scoping review
por: Regan, Lydia, et al.
Publicado: (2021)

Evidence-Informed Deliberative Processes for HTA Around the Globe: Exploring the Next Frontiers of HTA and Best Practices Comment on "Use of Evidence-informed Deliberative Processes by Health Technology Assessment Agencies Around the Globe"
por: Gopinathan, Unni, et al.
Publicado: (2020)

Back to the future, again: greater leadership, collaboration and accountability to accelerate progress to end TB
por: Weil, Diana, et al.
Publicado: (2018)

New global commitment to end tuberculosis
Publicado: (2017)

UNITE4TB: a new consortium for clinical drug and regimen development for TB
por: Boeree, M. J., et al.
Publicado: (2021)

Learning organizations, internal marketing, and organizational commitment in hospitals
por: Tsai, Yafang
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_4d1f1cjr7pa0alverjebqf0o2s